Elixi, Author at Elixi International - Page 13 of 13

4 March 2019

Palynziq (pegvaliase), new treatment for phenylketonuria, a rare inherited metabolic disease

0 Comments3 Minutes

4 March 2019

Zynquista (sotagliflozin), New add-on treatment to insulin for treatment of certain patients with type 1 diabetes

0 Comments4 Minutes

18 February 2019

The World Health Organisation issues an alert on falsified ICLUSIG traded globally

0 Comments2 Minutes

10 February 2019

Forxiga and Edistride (Dapagliflozin) recommended by EMA as first oral add-on treatment to insulin for treatment of certain patients with type 1 diabetes

0 Comments5 Minutes

7 February 2019

Cablivi (caplacizumab-yhdp) approved by FDA for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP)

0 Comments4 Minutes

25 January 2019

First generic version of Sabril (vigabatrin) approved by FDA for the treatment of complex partial seizures

0 Comments3 Minutes

25 January 2019

Ultomiris (ravulizumab), approved by FDA for the treatment of paroxysmal nocturnal hemoglobinuria (PNH)

0 Comments5 Minutes

11 January 2019

European Commission Approves Merck’s DELSTRIGO (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen for the Treatment of HIV-1 in Appropriate Patients

0 Comments2 Minutes

7 January 2019

FDA approves Elzonris (tagraxofusp-erzs), first treatment for rare blood disease

0 Comments3 Minutes